Report Highlights
The global market for central nervous system (CNS) biomarkers is estimated to grow from $7.6 billion in 2025 to reach $13.8 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12.6% from 2025 through 2030.
Report Includes
- 141 data tables and 44 additional tables
- An up-to-date overview and analysis of the global market for central nervous system (CNS) biomarkers
- In-depth analysis of global market trends, featuring historical revenue data for 2022-2024, estimated figures for 2025, as well as forecasts for 2030, including projections of CAGRs through 2030
- Analysis of market opportunities with a holistic review of Porter’s Five Forces model and industry supply chain analysis, considering both micro- and macro-environmental factors prevailing in the market
- Explanation of market drivers, restraints and other forces impacting the global market
- Discussion of CNS disease segments, prevalence and gaps in treatment for Alzheimer’s disease, depression, Parkinson’s disease, multiple sclerosis, etc.
- Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, regulatory framework and reimbursement scenarios
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the practices of leading companies
- Identification of companies best positioned to meet this demand due to their proprietary technologies, mergers and acquisitions, joint ventures and other strategic alliances
- Profiles of the leading global companies, including Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Siemens Healthineers, Abbott and Bio-Rad Laboratories Inc.
Report Scope
The report examines and segments the global central nervous system (CNS) biomarkers market by disease, application, technology and biomarker type. It also provides insights into emerging trends and potential growth drivers. The report focuses on Alzheimer’s disease, multiple sclerosis, amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson’s disease and others. By application, it examines drug discovery and development, clinical diagnostics and personalized medicine. By technology, proteomics, molecular imaging and genomics are reviewed. Finally, biomarker types such as amyloid-beta, tau protein and others are considered.
The report also provides an inclusive regional analysis covering North America, Europe, Asia-Pacific, South America and the Middle East and Africa. It evaluates the impact of AI adoption on the CNS biomarkers industry and market dynamics, including drivers, challenges and emerging trends, while highlighting innovations in product and performance enhancements. The study concludes with an analysis of major market participants and their offerings.
Global revenue ($ million) for the base year of 2024, estimates for 2025 and data for the forecast period 2025 through 2030 are also part of the report.
Report Synopsis
| Report Metrics | Details | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Base year considered | 2024 | ||||||||||||||||
| Forecast period considered | 2025-2030 | ||||||||||||||||
| Base year market size | $6.9 Billion | ||||||||||||||||
| Market size forecast | $13.8 Billion | ||||||||||||||||
| Growth rate | CAGR of 12.6% from 2025 to 2030 | ||||||||||||||||
| Units considered | $ Millions | ||||||||||||||||
| Segments covered | By Disease, Application, Technology, Biomarker Type, and Region | ||||||||||||||||
| Regions covered | North America, Europe, Asia-Pacific, South America, and the Middle East and Africa (MEA) | ||||||||||||||||
| Countries covered | The U.S., Canada, Mexico, Brazil, Argentina, Japan, China, India, South Korea, Australia, Germany, the U.K., France, Italy, and Spain | ||||||||||||||||
| Key Market Drivers |
|
||||||||||||||||
| Companies studied |
|
||||||||||||||||
Frequently Asked Questions (FAQs)
- Increasing prevalence of neurological disorders.
- Advancements in diagnostic technologies and research.
- Rising focus on early detection and personalized medicine.
- High cost of advanced diagnostic assays.
- Regulatory and validation challenges.
- Limited awareness and adoption among healthcare providers.
- Growth in neurodegenerative disease research.
- Expansion of early diagnosis and screening programs.
- Integration with personalized medicine.
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
Consulting Editor’s Credentials
Mariana Kuznietsova, a Life Science Consultant at BCC Research, has 8 years of experience in both academic and industry research developing biochemical and biotechnological applications and laboratory services. She also has a strong background in laboratory equipment trading services covering technical support, complex lab solutions to meet demands of laboratories from a range of areas, such as Academia, Agriculture, Pharma, and Food and Beverage. Mariana holds a Ph.D. in Biochemistry from the Taras Shevchenko National University of Kyiv, Ukraine.
Related Reports
Biomarkers: Technologies and Global Markets
The global market for biomarkers was valued at $63.7 billion in 2023. This market is expected to grow from $70.5 billion in 2024 to $130.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 13.1% from 2024 through 2029.
Oncology Biomarkers: Global Markets
The global oncology biomarkers market reached $15.5 billion in 2022, should reach $17.6 billion by 2023 and $35.2 billion by 2028 with a compound annual growth rate (CAGR) of 14.9% during the forecast period of 2023-2028.
Cardiac Biomarkers: Technologies and Global Markets
The global market for cardiac biomarkers is estimated to increase from $13.4 billion in 2022 to reach $23.8 billion by 2027, at a compound annual growth rate (CAGR) of 12.2% from 2022 through 2027.
Renal Biomarkers: Technologies and Global Markets
The global market for renal biomarkers is estimated to increase from $1.2 billion in 2022 to reach $1.7 billion by 2027, at a compound annual growth rate (CAGR) of 7.6% from 2022 through 2027.
Track the Latest Global Tariff Developments
In today's fast-paced global economy, tariffs are no longer static—they are dynamic levers shaped by geopolitical realignments, supply chain vulnerabilities, inflationary pressures, and sustainability-driven trade reforms. As governments worldwide recalibrate their trade strategies, businesses are left to navigate a maze of shifting rules, rising costs, and regulatory uncertainty.
Our analysis empowers you with real-time updates and in-depth expert analysis on all facets of global tariff activity. From new trade agreements and sanctions to abrupt tariff hikes and retaliatory duties, we monitor developments across borders, sectors, and industries—so you don't have to.
Whether it's the ongoing U.S.–China trade dynamics, the evolving EU Carbon Border Adjustment Mechanism (CBAM), or the emerging policies in India, ASEAN, and Latin America, we provide full-spectrum coverage. We also track multilateral trade negotiations, World Trade Organization (WTO) rulings, and sector-specific duty structures—ensuring you are always ahead of global trade shifts.
With our analysis, you can stay informed, identify risks, and confidently respond to tariff changes—no matter where you operate.
Ready to see what tariff means for your business?
Consult with our experts or request your custom Tariff Impact Brife today
Stay Informed, Stay Competitive
In today's interconnected and unpredictable global economy, staying ahead of tariff shifts is not just important—it's essential. BCC Research provides decision-makers with trusted, research-driven insights that turn uncertainty into opportunity.
Our in-depth market analysis and trade intelligence help you decode how tariff changes impact your specific sector—manufacturing, healthcare, technology, agriculture, or energy. We break down complex data into actionable knowledge through comprehensive reports, expert commentaries, and sector-focused forecasts.
Our analysis includes:
- Thorough breakdowns of current and proposed tariff policies and how they affect regional and global trade flows.
- Sector-specific implications, helping you understand the strategic impact on sourcing, pricing, and competitiveness.
- Forward-looking insights to support risk management, planning, and response strategies for evolving trade conditions.
With BCC Research, you gain more than just information—you gain clarity and confidence to make well-informed decisions in a volatile trade environment.
Don't let tariffs catch you off guard—let our insights guide your strategy.
Recent Reports
Decentralized Clinical Trials: Global Markets
The report provides an overview of the global decentralized clinical trials (DCT) market and analyzes market trends. It includes global revenue ($ Million) for the base year data of 2024 and for the forecast period 2025 through 2030.
Central Nervous System (CNS) Biomarkers: Technologies and Global Markets
The global market for central nervous system (CNS) biomarkers is estimated to grow from $7.6 billion in 2025 to reach $13.8 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12.6% from 2025 through 2030.
Stem Cell and Regenerative Therapy: Global Markets
The global market for stem cell and regenerative therapy is projected to grow from an estimated $16.7 billion in 2025 to $43.8 billion by 2030, at a compound annual growth rate (CAGR) of 21.3% from 2025 to 2030.
Cell and Gene Therapy Tools and Reagents: Global Markets
The global market for cell and gene therapy tools and reagents is expected to grow from $12 billion in 2025 and is projected to reach $19.8 billion by the end of 2030, at a compound annual growth rate (CAGR) of 10.6% during the forecast period of 2025 to 2030.
Mesotherapy: Global Markets
The report analyzes trends in the global mesotherapy market and segments the market by product type, application, ingredient type and end user, while focusing on trends and challenges that affect the market. It includes analysis of the competitive landscape with company ranking and offers company profiles covering financials, product portfolios and recent developments.
Top Trending Reports
Genetic Modification Therapies Clinical Applications: Gene Therapies, Genetically Modified Cell Therapies, RNA Therapies and Gene Editing
The global market for genetic modification therapies is estimated to grow from $14.8 billion in 2025 to reach $32.1 billion by the end of 2030, at a compound annual growth rate (CAGR) of 16.8% from 2025 through 2030.
State of the Life Sciences Industry - Fourth Quarter Review
State of the Life Sciences Industry Market Report delivers insights on biotech, pharma, medical devices, innovation trends, and global market outlook.
Carbon Fiber: Global Markets
The global market for carbon fiber was valued at $4.9 billion in 2024 and is estimated to increase from $5.3 billion in 2025 to reach $8.2 billion by 2030, at a compound annual growth rate (CAGR) of 9.1% from 2025 through 2030.
Global Markets for Diabetes Therapeutics and Diagnostics
The global market for diabetes therapeutics and diagnostics is estimated to grow from $134.9 billion in 2025 to reach $241.5 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12.4% from 2025 through 2030.
Sleep Aids: Technologies and Global Markets
The global market for sleep aid technologies is estimated to grow from $103.5 billion in 2025 to reach $136 billion by 2030, at a compound annual growth rate (CAGR) of 5.6% from 2025 to 2030.
Report Highlights
The global central nervous system (CNS) biomarkers market should reach $9.5 billion by 2027 from $5.7 billion in 2022 at a compound annual growth rate (CAGR) of 10.8% for the forecast period of 2022 to 2027.
Report Includes
- 43 tables
- An overview of the global market and technologies for central nervous system (CNS) biomarkers
- Estimation of the market size and analyses of market trends, with data from 2019 to 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
- Explanation of market drivers, restraints and other forces impacting the global market
- Description of technologies such as genomics, proteomics, and imaging, and assessments of their advantages and disadvantages.
- Discussion of CNS disease segments, prevalence, and gaps in treatment for Alzheimer’s disease, depression, Parkinson’s disease, multiple sclerosis, and others
- Coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
- Comprehensive company profiles of major players of the industry, including Abbott, Bio-Rad Laboratories Inc., Eisai Co. Ltd., Merck and Thermo Fisher Scientific Inc.
Report Highlights
The global CNS biomarker market is projected to reach $5.1 billion by 2020 from $3.1 billion in 2015, at a compound annual growth rate (CAGR) of 10.4%.
Report Includes
- An overview of the global market for central nervous system (CNS) biomarkers, which are measurable and quantifiable biological indicators that can be used to diagnose or predict disease, monitor disease progression, and predict treatment response.
- Analyses of global market trends, with data from 2014 and 2015, and projections of compound annual growth rates (CAGRs) through 2020.
- Evaluation of technologies such as genomics, proteomics, and imaging, and assessments of their advantages and disadvantages.
- Discussion of CNS disease segments, prevalence, and gaps in treatment for Alzheimer’s disease, depression, Parkinson’s disease, multiple sclerosis, and others.
- Patent analyses.
- Profiles of major players in the field.
Report Highlights
The global CNS biomarker market was estimated at $1.7 billion in 2011 and nearly $2 billion in 2012. The market is projected to reach $5.1 billion by the end of the forecast period of 2012 to 2017, representing a compound annual growth rate (CAGR) of 20.7%.
Report Includes
- An overview of the global market for central nervous system (CNS) biomarkers, which are measurable and quantifiable biological indicators that can be used to diagnose or predict disease, monitor disease progression, and predict treatment response.
- Analyses of global market trends, with data from 2010 through 2012, and projections of compound annual growth rates (CAGRs) through 2017.
- Evaluations of technologies such as genomics, proteomics, and imaging, and assessments of their advantages and disadvantages.
- Discussion of CNS disease segments, prevalence, and gaps in treatment for Alzheimer’s disease, depression, Parkinson’s disease, multiple sclerosis, and others.
- Patent analyses.
- Comprehensive company profiles of major players.
Report Highlights
-
The global CNS biomarker market was estimated at $1.3 billion in 2009 and is expected to reach close to $3.2 billion by 2015, with a compound annual growth rate (CAGR) of 17.1% from 2010 to 2015.
-
The CNS molecular diagnostic market will see the largest growth, with a compound annual growth rate (CAGR) of 172.3% from 2010 to 2015 due to the number of diagnostic tests that are in the pipeline. This sector is valued at $2 million in 2010 and is expected to be worth $302 million in 2015.
-
The growth rate for the CNS biomarker market for drug development will increase as more validated biomarkers become available for patient segmentation and assessment of efficacy for clinical trials. This sector is worth an estimated $162 million in 2010 and is expected to reach $355 million in 2015, a 17% compound annual growth rate (CAGR).
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More